iPS-39
FDCHi004-A
General
Donor Information
General Donor Information |
|
Sex | female |
Ethnicity | Chinese Han |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA7002468 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | the ethics committee of Children's Hospital of Fudan University |
Approval number | 2016-28 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | the ethics committee of Children's Hospital of Fudan University |
Approval number | 2016-28 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Genes | |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Selection criteria for clones | Manually picked |
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
|
|||
SOX2 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.